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BACKGROUND Gender-based data on chest pain after PCI with newer
generation DES are scarce. The aim of this study is to assess gender
differences in chest pain following percutaneous coronary interven-
tion (PCI) with newer generation drug-eluting stents (DES).
METHODS We performed a patient-level pooled analysis of the
TWENTE and DUTCH PEERS randomized trials that enrolled a broad
patient population, treated with newer generation permanent poly-
mer-coated DES. The primary clinical endpoint is target vessel failure
(TVF), a composite of cardiac death, target vessel-related myocardial
infarction (MI), or target vessel revascularization. At 1 and 2-years,
clinical follow-up was available in 99.9% and patient-reported chest
pain data in 94.1% and 93.6%.
RESULTS Among all 3,202 patients, the 871 (27.2%) women were
older (67.510.2 years vs. 62.810.6 years, p<0.001) and had more
cardiovascular risk factors than men, such as diabetes (24.2% vs.
17.8%, p<0.001), hypertension (63.6% vs. 51.6%, p<0.001), and a
positive family history for coronary disease (54.5% vs. 50.1%,
p¼0.03). At 1 and 2-year follow-up, women had more clinically
relevant chest pain than men (16.3% vs. 10.5%, p<0.001, and 17.2%
vs. 11.1%, p<0.001, respectively). Multivariate analysis demonstrated
that female gender independently predicted clinically relevant chest
pain at 1 and 2-year follow-up (adjusted OR:1.7, 95%-CI:1.4–2.2,
p<0.001; adjusted OR:1.6, 95%-CI:1.3–2.1, p<0.001, respectively).
Nevertheless, the 2-year rates of TVF (9.4% vs. 9.5%, p¼0.93) were
almost identical for both genders.
CONCLUSIONS While after PCI with newer generation DES the inci-
dence of adverse cardiovascular events was low and similar for both
genders, women showed a signiﬁcantly higher prevalence of clinically
relevant chest pain that appears to be largely related to mechanisms
other than epicardial coronary obstruction.
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BACKGROUND The ALPHA coronary stent delivery system includes a
cobalt-chromium, ﬂexible, thin-strut platform, a bio-stable and
biocompatible ﬂuoro-polymer based drug carrier, sirolimus and a
hydrophilic, rapid-exchange delivery catheter. It is designed to create
a competitive alternative to other drug-eluting coronary stents sys-
tems. Herein, we report the initial 2-year outcomes of 781 patients
(pts) treated with the ALPHA stent.
METHODS Consenting pts. were treated with one or more ALPHA
stents and followed by trained research coordinators. Angiographic
and follow-up angiography was evaluated by a central angiographic
core laboratory.
RESULTS Pts. averaged 58 years of age and 66% were male. Hyper-
tension was present in 57%. Most pts. presented with unstable angina
(78%). Sites of stent implantation included the LAD (55%), LCX (20%)
and RCA (25%). Based on angiographic core lab measurements,
average lesion length was 21 mm and average reference diameter was
2.8mm. Most pts. (69%) had a single lesion treated and 1.6 stents were
deployed per pt. Transradial access was used in 83%. Two-year
follow-up was available in 768 (98%) pts. The incidence of all-cause
death was 0.9% with cardiac death being 0.4%. The rate of target
lesion revascularization was 0.7%. Myocardial infarction was
observed in 1.3%. Importantly total MACE was 2.2% and no pt.experienced thrombosis of the Alpha stent. Angiographic follow-up
was completed in 87% of 205 pts. Lesion length and reference diam-
eter were 21þ13 mm and 2.8þ0.7mm respectively. In-stent late loss
was 0.07 mm and in-segment late loss was 0.04: mm. Binary reste-
nosis rate was 1.0%.
CONCLUSIONS The ALPHA stent was designed on the basis of the
most contemporary knowledge of stent technology. This observa-
tional study demonstrates the ALPHA stent can achieve high rates of
sustained patency with low rates of stent-related adverse events.
CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS Stent, Stenting, coronary
TCT-595
Randomized Comparison Of The New ALPHA And The EXCEL Stents:
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BACKGROUND Stent thrombosis (ST) is an undesirable consequence
of intracoronary stents, commonly presenting as myocardial infarc-
tion and at times death. Efforts to reduce the occurrence of ST have
included the use of biodegradable polymers. Whether this modiﬁca-
tion of stent design reduces ST is unclear
METHODS The ALPHA coronary stent includes a ﬂexible, cobalt-
chromium platform, a bio-stable and bio-compatible ﬂuoro-polymer
based drug carrier and sirolimus. We conducted a randomized, sin-
gle blinded trial to compare the angiographic (9-months) and clinical
(12-months) outcomes of ALPHA (n¼205) to EXCEL (n¼202), also a
sirolimus eluting stent but with a bio-degradable polymer.
RESULTS There were no signiﬁcant (p>0.05) differences in baseline
clinical or angiographic features, number of stents deployed or
initial success rates. At 9-months, angiographic late loss (angio-
graphic core laboratory, LL) was 0.07 mm and 0.10 mm (P¼NS) in
ALPHA and EXCEL stents respectively. Maximal LL across stent
segments was lower in ALPHA compared to EXCEL patients
(0.20mm vs. 0.25mm, p¼0.02). At 12-months, clinical events were
low in both stent groups (table). No patient receiving the ALPHA
stent experienced ST while ST was observed in 0.5% of those treated
with EXCEL.
CONCLUSIONS Excellent angiographic and clinical results, including
avoiding stent thrombosis, may be obtained with the ALPHA sirolimus
eluting stent and a stable polymer.Event at 12-months ALPHA EXCEL P valueAll Cause Death 0.5% 1.0% 0.22Myocardial Infarction 1.0% 1.5% 0.69Any TLR 1.5% 3.0% 0.09ARC Thrombosis 0% 0.5% 0.50CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS Sirolimus, Stent development, Stent thrombosis, late
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BACKGROUND Fast releasing, rapamycin eluting stents although
safe, showed inferior results with regard to inhibition of restenosis.
Therefore, we report vascular effects of the novel, biodegradable
polymer stent matrix with elevated sirolimus dose and fast release
kinetics (ed-frSES, Alex, Balton) in the porcine coronary in stent
restenosis model.
METHODS A total of 19 stents were implanted with 120% overstretch
in coronary arteries of 7 domestic pigs: 7 ed-frSES with 1.3 mg/mm2 of
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B243sirolimus, 8 frSES with 1 mg/mm2 of sirolimus and 8 bare metal stents.
Following 28 days, coronary angiography was performed, animals
sacriﬁced and stented segments harvested for histopathological
evaluation.
RESULTS In angiography at 28 days, the late lumen loss was lowest in
the elevated dose SES (ed-frSES: 0.200.2 vs. frSES 0.800.5 vs. BMS:
0.960,50.5 mm, p<0,01). This was conﬁrmed in the morphometric
evaluation in histopathology as represented by signiﬁcant and dose
dependent decrease in percent area stenosis (ed-frSES: 22.412.7% vs.
frSES: 3510.7% vs. BMS: 47.512.5%; p<0,01). There was no peri-
strut inﬂammation in any of the groups. Endothelialisation score was
numerically, however not meaningfully decreased in ed-frSES (ed-
frSES: 2.93 vs. 3. vs. 3; p¼0,05). Signs of ﬁbrin were also noted in ed-
frSES (ed-frSES: 0,4 vs. frSES: 0 vs. BMS: 0, p¼0,05).
CONCLUSIONS Sirolimus dose dependent vascular response was re-
ported. The elevated dose, fast releasing SES shows satisfactory
vascular healing, similar to regular dose, fast release SES, with
improved efﬁcacy in restenosis inhibition.
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BACKGROUND Percutaneous coronary intervention (PCI) of coronary
calciﬁed lesions has been associated with worse clinical outcomes
compared to non-calciﬁed lesions. However, the impact of coronary
calciﬁcations (CC) two years after drug-eluting stent (DES) PCI is un-
known. We sought to evaluate the frequency and impact of CC two
years after DES PCI from the large ADAPT-DES registry.
METHODS ADAPT-DES was a prospective, multicenter “all-comers”
registry of consecutive patients successfully treated with at least one
DES. Two-year outcomes were analyzed according to the presence of
CC as assessed by the enrolling site operator.
RESULTS A total of 8,578 patients underwent DES PCI; CC of at least
one target lesion was present in 2,646 patients (30.8%). Patients with
CC were older, more frequently had diabetes, hypertension, dyslipi-
demia, renal insufﬁciency, left main or LAD disease, and multivessel
intervention, with more stents implanted. IVUS was used equally in
both groups. Second-generation DES were implanted less frequently
among patients with CC (60.5% vs. 64.7%, p¼0.0002). At two years,
CC patients had higher unadjusted rates of adverse ischemic and
bleeding events (Table). By multivariable analysis, the presence of CC
was a strong independent predictor of death (HR [95%CI] ¼ 4.92 [1.29,
18.80], myocardial infarction (HR [95%CI] ¼ 1.67 [1.26-2.23],p¼0.0004), MACE (HR [95%CI] ¼ 1.82 [1.37, 2.41], p<0.0001 and major
bleeding (HR [95%CI] ¼ 1.76 [1.44-2.16], p<0.0001).Calciﬁed lesions
(N[2,646)Non-calciﬁed lesions
(N[5,932) P-valueAll-cause death 4.8% (124) 3.5% (192) 0.003Cardiovascular 2.8% (73) 2.3% (124) 0.09Non-cardiovascular 2.0% (51) 1.2% (68) 0.008Myocardial infarction 6.4% (135) 4.0% (226) <0.0001ST deﬁnite/probable 1.2% (30) 1.1% (63) 0.82Any revascularization 21.7% (574) 19.7% (1167) 0.03Clinically-driven
TVR10.0% (264) 8.8% (525) 0.09Clinically-driven TLR 5.8% (153) 5.4% (322) 0.50Target vessel failure 18.2% (471) 14.2% (801) <0.0001MACE* 12.8% (329) 9.9% (556) <0.0001Major bleeding 14.0% (370) 6.2% (369) <0.0001Values are Kaplan-Meier estimates presented as % (n). TVR ¼ target vessel revascularization; ST ¼ stent
thrombosis; TLR ¼ target lesion revascularization; *MACE ¼ major adverse cardiovascular events, deﬁned as
the composite of cardiac death, myocardial infarction, or ischemia-driven target lesion revascularization;
target vessel failure ¼ the composite of cardiac death, target vessel revascularization, and MI.
CONCLUSIONS Target lesion CC as assessed by the interventionalist
is relatively frequent, being present in approximately one-third of
patients undergoing PCI. CCA was strongly predictive of adverse
ischemic and bleeding events 2 years after DES PCI.
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BACKGROUND Multiple coronary artery disease (CAD) including diabetic
patients (pts) remained a challenge for percutaneous coronary in-
terventions (PCI). Introduction of newer generation of drug eluting stent
(DES) signiﬁcantly improved safety and efﬁcacy compared with the pre-
vious ones although its value in pts with complex CAD in comparison with
1st generation DES is not established yet.
METHODS From March 2013 to February 2014, 225 pts with complex
CAD undergoing DES implantation in 15 centers in Argentina were
prospectively included. The registry was approved by local regula-
tory authorities and monitored by an independent safety committee.
Primary endpoint was to assess the incidence of major adverse car-
diovascular events (MACCE) deﬁned as death, myocardial infarction
(MI) stroke and unplanned new revascularization (TVR) using Fire-
bird-2 (2nd generation chromo-cobalt rapamycin eluting stent,
Microport Medical Co, Shanghai) vs. ERACI III population (DES arm)
at long term follow-up. Inclusion criteria were indication of
myocardial revascularization in 2, 3 major coronary arteries and/or
unprotected left main disease (ULMD). Exclusion criteria were poor
ejection fraction (<35%), recent ST elevation MI, previous DES,
lesion diameter < 2.5 mm, renal failure and contraindications for
dual antiplatelet therapy (DAPT). Stent thrombosis was analyzed. All
revascularization was done by intention-to-treat-principle and op-
erator’s advice was to treat only lesions  70% of diameter stenosis
in vessels with, at least, 2.0 mm of reference diameter, to fulﬁll a
modiﬁed in SYTNAX score. In ERACI IV the only DES allowed was
Firebird-2, whereas in ERACI III 1st DES generation was used. All
patients received DAPT for one year.
RESULTS Mean age of the 225 pts was 64.5 þ/- 11.0 years, with 30.6%
diabetics and 67.7% with 3 vessels or ULMD. Modiﬁed SYNTAX score
was 22 þ/- 11 and we implanted 1.7 þ/- 1.8 Firebird-2 per patient,
similar to the ERACI III DES arm (1.79), p¼0.8. Stent length was
41.4 mm þ/- 10.8 vs 36.1 mm þ/- 8.9 in ERACI IV and ERACI III,
